Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy.
CONCLUSION: Clarity of diagnostic criteria for myocarditis remains a challenge. Observation bias may, in part, influence higher reported rates in Australia. Monitoring for myocarditis is warranted in the first 4 weeks, and treatment of comorbid metabolic syndrome and diabetes may reduce the risk of cardiomyopathy. The risks of myocarditis and cardiomyopathy are low and should not present a barrier to people with treatment refractory schizophrenia being offered a monitored trial of clozapine.
PMID: 31957459 [PubMed - as supplied by publisher]
Source: The Australian and New Zealand Journal of Psychiatry - Category: Psychiatry Authors: Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, Kisely S Tags: Aust N Z J Psychiatry Source Type: research
More News: Australia Health | Cardiology | Cardiomyopathy | Diabetes | Drugs & Pharmacology | Endocrinology | Heart | Metabolic Syndrome | Myocarditis | New Zealand Health | Psychiatry | Schizophrenia | Study